Accueil   Diary - News   All news IXALTIS strengthens its portfolio by entering into an agreement with XIGEN

IXALTIS strengthens its portfolio by entering into an agreement with XIGEN

 

Toulouse (31) / Archamps (74), October 2nd, 2017 - Ixaltis, the start-up specialized in developing treatments for urogenital disorders, and Xigen, a privately-owned biopharmaceutical company that specializes in the development of peptides for use against inflammation, have signed an option agreement for exclusive worldwide rights to one compound in urogenital diseases.

 

 

Following this agreement, Ixaltis will perform preclinical proof of concept (POC) for two of Xigen’s compounds - XG-102 and XG-104 - in animal models and human tissues. XG-102, an innovative JNK inhibitor, has been successfully tested in clinical trials for ocular diseases and is already licensed out for another promising indication. XG-104, a second JNK inhibitor, is an L/D-amino-acids peptide.

 

 

Read the press release